about
Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trialsCurrent and emerging treatment strategies for Duchenne muscular dystrophyRedox Characterization of Functioning Skeletal MuscleAssessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging optionsModel organisms in the fight against muscular dystrophy: lessons from drosophila and ZebrafishUpper extremity 3-dimensional reachable workspace analysis in dystrophinopathy using KinectAAV-mediated overexpression of human α7 integrin leads to histological and functional improvement in dystrophic miceOnline self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefitsDystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel TherapiesA Reduction in Selenoprotein S Amplifies the Inflammatory Profile of Fast-Twitch Skeletal Muscle in the mdx Dystrophic Mouse.Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trialsHigh throughput screening in duchenne muscular dystrophy: from drug discovery to functional genomicsA new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic programAbsence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.miR-29 targets Akt3 to reduce proliferation and facilitate differentiation of myoblasts in skeletal muscle development.'Double trouble': diagnostic challenges in Duchenne muscular dystrophy in patients with an additional hereditary skeletal dysplasiaOxidative stress and pathology in muscular dystrophies: focus on protein thiol oxidation and dysferlinopathies.Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies.Myostatin--the holy grail for muscle, bone, and fat?Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disordersCystic fibrosis newborn screening: a model for neuromuscular disease screening?Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy.Costamere proteins and their involvement in myopathic processes.Skeletal Muscle Microvasculature: A Highly Dynamic Lifeline.Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophyComputer task performance by subjects with Duchenne muscular dystrophy.Increased Circulating Levels of Interleukin-6 Induce Perturbation in Redox-Regulated Signaling Cascades in Muscle of Dystrophic Mice.Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.Myofiber-specific inhibition of TGFβ signaling protects skeletal muscle from injury and dystrophic disease in mice.Reducing sarcolipin expression mitigates Duchenne muscular dystrophy and associated cardiomyopathy in mice.Cost of illness for neuromuscular diseases in the United States.Correlation of knee strength to functional outcomes in Becker muscular dystrophy.Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle.Glucocorticoids Improve Myogenic Differentiation In Vitro by Suppressing the Synthesis of Versican, a Transitional Matrix Protein Overexpressed in Dystrophic Skeletal Muscles.Utrophin up-regulation by artificial transcription factors induces muscle rescue and impacts the neuromuscular junction in mdx mice.Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics.Oxidative stress in Duchenne muscular dystrophy: focus on the NRF2 redox pathway.Human Galectin-1 Improves Sarcolemma Stability and Muscle Vascularization in the mdx Mouse Model of Duchenne Muscular Dystrophy
P2860
Q26741409-E2FCF75D-06C7-4F38-B451-4CE492F1EBE5Q26741535-F85FA661-11B0-4E43-8896-E88AC1CBD930Q26774782-94A1660D-C27D-4D9B-A870-9F8713A57ED5Q26785627-D0E35D17-91EF-438E-8F59-67127B5D9118Q26991681-5C50A549-BE0F-4595-A068-7EA6CAD94D7FQ27332140-2E5CD42E-8141-4E21-B53D-1FF491C38392Q28283362-EC35D298-27BE-460A-AE68-00187871B95CQ28544012-EC9963CE-0A84-4E24-B70B-F41CF8B7B2F6Q33608478-8BDC73FE-38BF-4047-A65D-2371753E7505Q33737817-15F82923-BF88-4BD1-9253-FF4E8D8886FCQ33991780-192F18FE-8C9B-498B-B274-63AE6EA20098Q34152280-C029831F-DAF6-4215-8A34-1243CDDCB965Q34792390-456CEF17-C049-42DE-991F-A70E45D4DD48Q36179162-10B66519-D8D9-4059-80A2-818A56CF0135Q36371465-CFAB6630-D960-46B4-95A5-B0E41BBDF4BEQ36422465-9B0BC376-3B63-4CEE-8BEA-131A5930A668Q36973754-A1339B78-5F78-44F4-A905-AB2A7722FBF8Q37271982-6AABE221-CE7F-4071-AE75-4EB167A91FE0Q38075201-9C259925-5932-4757-9B00-C0B4B0BFC437Q38079633-82AC7321-B380-4F04-8204-3A894E42C691Q38144994-1D04D507-05F2-49BA-A97A-173BB51CE968Q38155361-55C04B27-52F6-462F-AEDB-207F757B2D04Q38271515-5681FB8E-8E51-4FE2-A2DF-5599881018A1Q38302852-C5ED6061-F806-4429-98AD-54BAC715D7AAQ38531654-AC0F2DB8-C0DC-4F2C-9631-285EB1BF2A6BQ38622645-E6AFCEFC-B50F-4940-9D85-4DAC28087530Q39410461-2640680E-A4FB-4FF6-8635-2CBD445A77C6Q41293319-584F36C8-39FB-4762-AD80-46A6B9085C0BQ41463502-6B7EEA72-968A-4DEF-AE6F-1FD1C20DCF03Q41527279-646F1EED-1C09-4A03-9699-FE2B3505D45EQ41979450-2B70AF9C-838F-4E12-8DC7-4E7C6C8CFFF8Q42380533-C01FCE66-5F1D-4D52-8C55-3BAF7E49776BQ43841798-A1448493-6D55-4984-B741-4BE099C76A05Q45752246-D6B7EFB2-3E24-48C1-B764-620BA462735BQ47151990-7EB39A21-13BB-402B-A512-E9F8080542E3Q47324398-05D90212-3C1E-41FE-AA3E-F3CC4BEFEE28Q48510459-CFF06610-125D-4CC4-8CC7-AB4206F3F76EQ52372774-0BE31D49-5A6F-4AD8-8EAC-0F628E5FD076Q53498216-B9D3C671-D590-4A5E-AC9E-BF0F716D4529Q61811913-d88e0ed8-4dc1-b43a-c9fe-ed79f3de8709
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Emerging drugs for Duchenne muscular dystrophy
@ast
Emerging drugs for Duchenne muscular dystrophy
@en
type
label
Emerging drugs for Duchenne muscular dystrophy
@ast
Emerging drugs for Duchenne muscular dystrophy
@en
prefLabel
Emerging drugs for Duchenne muscular dystrophy
@ast
Emerging drugs for Duchenne muscular dystrophy
@en
P2093
P2860
P1476
Emerging drugs for Duchenne muscular dystrophy
@en
P2093
Jerry R Mendell
Louise R Rodino-Klapac
Vinod Malik
P2860
P304
P356
10.1517/14728214.2012.691965
P407
P577
2012-06-01T00:00:00Z